

Reconciliation of results and studies included.

	Current (August, 2020) PMID 32805168	Giustozzi, May 2020 PMID 31104194	Fuentes, 2019 ^a PMID 31685262	Wongsaengsak, 2019 DOI 10.1182/blood-2019-125473	Brunetti, 2019 PMID 31654194
Outcome(s)					
Venous thromboembolism recurrence					
Effect size	OR: 0.59 (0.41-0.86)	RR: 0.62 (0.43-0.91)	OR: 0.48 (0.24-0.96)	RR: 0.48 (0.26-0.87)	RR: 0.56 (0.40-0.79)
Heterogeneity	25%	30%	46%	56%	59%
Major bleeding					
Effect size	OR: 1.34 (0.83-2.18)	RR: 1.31 (0.83-2.08)	OR: 1.70 (1.04-2.78)	RR: 1.55 (0.79-3.04)	RR: 1.53 (0.95-2.47)
Heterogeneity	28%	23%	2%	29%	28%
Summary of important differences or findings	Included findings at 12 months for HOKUSAI VTE trial.				
Studies included					
Raskob (HOKUSAI-VTE), 2018 PMID 29231094	Yes*	Yes	Yes	Yes	Yes
Young (SELECT-D), 2018 PMID 29746227	Yes	Yes	Yes	Yes	Yes
McBane (ADAM-VTE), 2019 PMID 28837207	Yes	Yes	Yes	Yes	Yes
Agnelli (CaraVaggio), 2020 PMID 32223112	Yes	Yes	NA	NA	NA
Notes:					
* Outcomes reported at 12 months for HOKUSAI VTE trial were used in the current analysis.					